Atossa Therapeutics (NASDAQ:ATOS) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Atossa Therapeutics (NASDAQ:ATOS) announced its quarterly earnings data on Tuesday. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01, Zacks reports.

Atossa Therapeutics Trading Down 3.3 %

Shares of ATOS opened at $0.72 on Wednesday. Atossa Therapeutics has a twelve month low of $0.66 and a twelve month high of $2.31. The firm has a market capitalization of $91.05 million, a P/E ratio of -3.29 and a beta of 1.20. The stock’s fifty day simple moving average is $0.80 and its 200 day simple moving average is $1.11.

Institutional Investors Weigh In On Atossa Therapeutics

An institutional investor recently raised its position in Atossa Therapeutics stock. Bank of America Corp DE grew its position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 51.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 111,475 shares of the company’s stock after purchasing an additional 37,809 shares during the period. Bank of America Corp DE owned approximately 0.09% of Atossa Therapeutics worth $105,000 as of its most recent SEC filing. 12.74% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ATOS has been the subject of several recent analyst reports. Ascendiant Capital Markets lifted their price target on Atossa Therapeutics from $6.50 to $7.00 and gave the company a “buy” rating in a report on Monday, December 9th. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Atossa Therapeutics in a research report on Wednesday.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.